Crinetics Pharmaceuticals Hosts R&D Day Highlighting Preclinical Pipeline Progress

Details

Key updates included: 1) CRN12755, a TSHR antagonist for Graves' disease, showed promising results in reducing thyroid hormone levels and suppressing cytokine production in a rat model. 2) CRN10329, an SST3 agonist for autosomal dominant polycystic kidney disease (ADPKD), demonstrated decreased cyst growth and cellular proliferation in a mouse model. 3) CRN09682, a nonpeptide drug conjugate for neuroendocrine tumors, showed potent anti-tumor activity in preclinical models. The company also outlined future clinical trial plans for CRN09682, including a Phase 1/2 study. These updates were made available under the 'Investors' section of the company's website.

Items reported

Exhibits (1)

About Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.